Classification of nodal T-cell lymphoma based on expression of Th1-associated chemokine receptors, CXCR3 and CCR5, Th2-associated marker, ST2(L), and activated TCR OX40/CD134
. | OX40 (n = 162) . | . | CCR5 (n = 162) . | . | CXCR3 (n = 172) . | . | ST2(L) (n = 175) . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | + . | - . | + . | - . | + . | - . | + . | - . | ||||
| Unspecified | 9 (17) | 43 (83) | 13 (25) | 38 (75) | 25 (42) | 35 (58) | 21 (34) | 40 (66) | ||||
| Large | 5 (19) | 22 (81) | 5 (20) | 20 (80) | 12 (44) | 17 (56) | 12 (44) | 17 (56) | ||||
| Medium | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 3 (38) | 5 (62) | 2 (29) | 5 (71) | ||||
| Pleo (L and M/M) | 4 (25) | 12 (75) | 6 (38) | 10 (62) | 6 (40) | 9 (60) | 5 (31) | 11 (69) | ||||
| Pleo (small) | 0 (0) | 5 (100) | 2 (40) | 3 (60) | 3 (60) | 2 (40) | 2 (40) | 3 (60) | ||||
| Lennert | 0 (0) | 4 (100) | 0 (0) | 4 (100) | 1 (33) | 2 (67) | 0 (0) | 4 (100) | ||||
| AILD | 25 (96) | 1 (4) | 8 (29) | 20 (71) | 25 (89) | 3 (11) | 0 (0) | 28 (100) | ||||
| ALCL | 0 (0) | 18 (100) | 16 (89) | 2 (11) | 4 (24) | 13 (76) | 17 (94) | 1 (6) | ||||
| Lymphoblastic | 0 (0) | 19 (100) | 0 (0) | 18 (100) | 4 (18) | 18 (82) | 0 (0) | 21 (100) | ||||
| ATLL (lymphomatous) | 5 (11) | 42 (89) | 9 (19) | 38 (81) | 11 (24) | 34 (76) | 23 (49) | 24 (51) | ||||
. | OX40 (n = 162) . | . | CCR5 (n = 162) . | . | CXCR3 (n = 172) . | . | ST2(L) (n = 175) . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | + . | - . | + . | - . | + . | - . | + . | - . | ||||
| Unspecified | 9 (17) | 43 (83) | 13 (25) | 38 (75) | 25 (42) | 35 (58) | 21 (34) | 40 (66) | ||||
| Large | 5 (19) | 22 (81) | 5 (20) | 20 (80) | 12 (44) | 17 (56) | 12 (44) | 17 (56) | ||||
| Medium | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 3 (38) | 5 (62) | 2 (29) | 5 (71) | ||||
| Pleo (L and M/M) | 4 (25) | 12 (75) | 6 (38) | 10 (62) | 6 (40) | 9 (60) | 5 (31) | 11 (69) | ||||
| Pleo (small) | 0 (0) | 5 (100) | 2 (40) | 3 (60) | 3 (60) | 2 (40) | 2 (40) | 3 (60) | ||||
| Lennert | 0 (0) | 4 (100) | 0 (0) | 4 (100) | 1 (33) | 2 (67) | 0 (0) | 4 (100) | ||||
| AILD | 25 (96) | 1 (4) | 8 (29) | 20 (71) | 25 (89) | 3 (11) | 0 (0) | 28 (100) | ||||
| ALCL | 0 (0) | 18 (100) | 16 (89) | 2 (11) | 4 (24) | 13 (76) | 17 (94) | 1 (6) | ||||
| Lymphoblastic | 0 (0) | 19 (100) | 0 (0) | 18 (100) | 4 (18) | 18 (82) | 0 (0) | 21 (100) | ||||
| ATLL (lymphomatous) | 5 (11) | 42 (89) | 9 (19) | 38 (81) | 11 (24) | 34 (76) | 23 (49) | 24 (51) | ||||
Data in parentheses represent the percentage of tumors. Pleo indicates pleomorphic.